Isoprinosine
(Synonyms: 异丙肌苷,Inosine pranobex,NP 113,NPT 10381) 目录号 : GC18042An immunomodulatory antiviral complex
Cas No.:36703-88-5
Sample solution is provided at 25 µL, 10mM.
Isoprinosine is a complex of acetaminobenzoic acid, dimethylaminoisopropanol, and inosine in a 3:3:1 ratio with immunomodulatory effects.
Immunotherapy is the treatment of disease by inducing, enhancing, or suppressing an immune response. Immunomodulatory regimens usually have fewer side effects than existing drugs, such as less potential for creating resistance when treating microbial disease.
In vitro: Previous study found that increasing concentrations of Isoprinosine (50-400 μg/mL) could produce progressively growing inhibitory effect on HHV-1 replication. The combination of 1000 IU/mL IFN-α and Isoprinosine could result in enhanced anti-HHV activity [1].
In vivo: Previous study demonstrated the positive effect of Isoprinosine treatment on persistent infection of Balb/c mice with murine gammaherpesvirus 68. Increased number of leukocytes, increased percentage of neutrophils, elevated levels of virus-neutralizing antibodies, reduced number of atypical lymphocytes and reduced virus titers were detected in the examined organs after a 14-day treatment. The positive effect of Isoprinosine therapy vanished after 120-150 days [2].
Clinical trial: A previous clinical study evaluating the safety of Isoprinosine for the treatment of patients with acute respiratory viral infections confirmed the efficacy of Isoprinosine versus placebo in healthy non-obese subjects less than 50 years of age with clinically diagnosed influenza-like illnesses [3].
References:
[1] Majewska A, Lasek W, Janyst M, Mynarczyk G. IN VITRO INfIBITION OF HHV-1 REPLICATION BY INOSINE PRANOBEX AND INTERFERON-α. Acta Pol Pharm. 2016 May-Jun;73(3):637-44.
[2] Janíková O, Anicová L, Briestenská K, Mistríková J. The effect of Isoprinosine treatment on persistent infection of Balb/c mice infected with murine gammaherpesvirus 68. Acta Virol. 2017;61(1):32-38. doi: 10.4149/av_2017_01_32.
[3] Beran J, alapová E, pajdel M; Isoprinosine Study (EWO ISO-2014/1) Team. Inosine pranobex is safe and effective for the treatment of subjects with confirmed acute respiratory viral infections: analysis and subgroup analysis from a Phase 4, randomised, placebo-controlled, double-blind study. BMC Infect Dis. 2016 Nov 7;16(1):648.
Cas No. | 36703-88-5 | SDF | |
别名 | 异丙肌苷,Inosine pranobex,NP 113,NPT 10381 | ||
化学名 | 1-(dimethylamino)-2-propanol 4-(acetylamino)benzoate inosine | ||
Canonical SMILES | OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C=NC3=C2NC=NC3=O)O1.OC(C4=CC=C(NC(C)=O)C=C4)=O.CC(O)CN(C)C.OC(C5=CC=C(NC(C)=O)C=C5)=O.CC(O)CN(C)C.OC(C6=CC=C(NC(C)=O)C=C6)=O.CC(O)CN(C)C | ||
分子式 | C10H12N4O5 • 3C9H9NO3 • 3C5H13NO | 分子量 | 1115.2 |
溶解度 | ≤14mg/ml in DMSO;2mg/ml in dimethyl formamide | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 0.8967 mL | 4.4835 mL | 8.967 mL |
5 mM | 0.1793 mL | 0.8967 mL | 1.7934 mL |
10 mM | 0.0897 mL | 0.4484 mL | 0.8967 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet